Appili Therapeutics Names Balboni as Its Inaugural Chief Scientific Officer
2 October 2018 - - Canadian biopharmaceutical company Appili Therapeutics Inc has named Dr. Armand Balboni as its first chief scientific officer, the company said. 
In his new role with Appili, Dr. Balboni is responsible for the company's clinical and scientific strategy, with a particular emphasis on overseeing the scientific aspects of Appili's government and industry collaborations and steering the company's clinical programs through regulatory and pre-commercialisation processes.
Balboni's over 20-year healthcare career encompasses medical and drug development experience across a range of civilian and military organisations. 
He is also a partner, senior advisor and member of the board of directors of the investment advisory firm Bloom Burton and Co.
Balboni served as the senior advisor on scientific, regulatory, and medical affairs for the companies within Bloom Burton's 'incubation' programme, advising some of the most recent promising young Canadian biotech companies.
Earlier in his career, Balboni completed a period of active duty in the US Army as the deputy director, Office of Regulated Activities and senior reviewer on the clinical pharmacovigilance team. 
Balboni's tenure in the ORA focused on regulatory filings (Emergency Use Authorizations, meetings, pre-sub filings etc.) for military-relevant medical products across all therapeutic areas.
In addition, Balboni completed a US Department of Defense fellowship at the US Food and Drug Administration's Center for Drug Evaluation and Research in the Division of Anti-infective Products, and in the Office of Counterterrorism and Emerging Threats.
He also served as the chief, Office of Research and Technology Application at the US Army Research Institute of Infectious Disease (USAMRIID).
His office was tasked with oversight of all strategic partnerships between USAMRIID and universities, US and foreign government agencies, and biotechnology and pharmaceutical companies.
Balboni has also held various academic teaching positions, including posts at Westfield State University, the University of Maryland University College, and currently as Assistant Professor in Chemistry and Life Sciences at the United States Military Academy at West Point. He completed his doctoral work in the MD/PhD programme at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School.
Appili Therapeutics was founded to advance the global fight against infectious disease.
ATI-1501 employs Appili's proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of pediatric and elderly patients with difficulty swallowing.
ATI-1503 is a drug discovery programme aimed at generating negamycin analogue candidates, a novel class of antibiotics with broad-spectrum activity against Gram-negative bacteria.
Via an in-licensing programme, Appili acquired the rights to ATI-1701, a vaccine for tularemia, removing risk from a weaponized bioterrorism pathogen.
Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies.